A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AXATILIMAB
AND CORTICOSTEROIDS AS INITIAL TREATMENT FOR CHRONIC GRAFT VERSUS-HOST DISEASE
- Registry ID
- INCA 34176-357
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- INCYTE CORPORATION
- Start date
- 2025-04-17
- Last update
- 2024-09-25
Conditions
Related clinical trials
- AN OPEN LABEL, MULTI-CENTER, PHASE IV ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE
COMPLETED A PRIOR GLOBAL NOVARTIS OR INCYTE SPONSORED RUXOLITINIB (INC424)
STUDY OR A STUDY OF RUXOLITINIB IN COMBINATION EITHER WITH PANOBINOSTAT
(LBH589) OR SIREMADLIN (HDM201) OR RINETERKIB (LTT462), AND ARE JUDGED
BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT
- A PHASE 2, OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AXATILIMAB IN COMBINATION WITH RUXOLITINIB IN PARTICIPANTS WITH NEWLY DIAGNOSED CHRONIC GRAFT-VERSUS-HOST DISEASE
- A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO EVALUATE EFFICACY AND SAFETY OF BELUMOSUDIL IN COMBINATION WITH CORTICOSTEROIDS VERSUS PLACEBO IN COMBINATION WITH CORTICOSTEROIDS IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH NEWLY DIAGNOSED CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED MULTICENTER STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE
- A RANDOMIZED, OPEN-LABEL PHASE II CLINICAL TRIAL COMPARING DURABLE OVERALL RESPONSE RATE (DOR) AT 56 DAYS IN PATIENTS WITH STEROID-RESISTANT SEVERE ACUTE GVHD AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION TREATED WITH DECIDUAL STROMAL CELLS (DSC) OR BEST AVAILABLE TREATMENT (BAT)
- A RANDOMIZED PILOT TRIAL COMPARING ANTI-THYMOCYTE GLOBULIN (ATG) WITH ATG PLUS POST TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR PROPHYLAXIS AGAINST ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE (GVHD) IN MATCHED DONOR HEMATOPOIETIC CELL TRANSPLANTS (HCT)
View on source registry